← Home
© 2024 - 2025 InsightfulValue.com. All rights reserved.
📢 Press Releases
Date | Press release |
---|---|
2025-05-30 01:00:00 | Genentech’s Fenebrutinib Maintains Near-complete Suppression Of Disease Activity And Disability Progression For Up To Two Years In People With Relapsing Multiple Sclerosis South san francisco, calif.--(business wire)--genentech, a member of the roche group (six: ro, rog; otcqx: rhhby), announced today new, 96-week data for fenebrutinib demonstrating that patients with relapsing multiple sclerosis (rms) maintained no disability progression and low levels of disease activity for up to two years. the latest results for this investigational bruton’s tyrosine kinase (btk) inhibitor from the phase ii fenopta open-label extension (ole) study were presented at the consor. |
2025-05-23 09:00:00 | Chmp Recommends Eu Approval Of Roche’s Itovebi For Pik3ca-mutated, Er-positive, Her2-negative, Advanced Breast Cancer Basel, 23 may 2025 - roche (six: ro, rog; otcqx: rhhby) announced today that the european medicines agency’s committee for medicinal products for human use (chmp) has adopted a positive opinion for itovebi™ (inavolisib), in combination with palbociclib (ibrance®) and fulvestrant, for the treatment of adult patients with pik3ca-mutated, oestrogen receptor (er)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer, following recurrence on or within 12 months of completing adjuvant endocrine treatment. if approved, the itovebi-based regimen has the potential to transform the standard of care in this first-line setting, where treatments are currently limited.1 a final decision regarding the approval is expected from the european commission in the near future. |
2025-05-23 01:10:00 | Roche Announces New Collaboration With Broad Clinical Labs To Accelerate Adoption Of Cutting-edge Sbx Sequencing Technology Basel, 23 may 2025 – roche (six: ro, rog; otcqx: rhhby) announced today a strategic collaboration with broad clinical labs to develop and pilot groundbreaking applications using roche’s recently unveiled next-generation sequencing (ngs) sequencing by expansion (sbx) technology. this collaboration will focus on harnessing the power of the sbx technology to transform clinical genomics and biomedical discovery. it will also aim to establish the sbx technology as a routine offering for fast, scalable sequencing for broad clinical lab’s research community. |
2025-05-23 01:00:00 | New Two-year Follow-up Of Genentech’s Columvi Extends Overall Survival In Relapsed Or Refractory Diffuse Large B-cell Lymphoma Patients South san francisco, calif.--(business wire)--genentech, a member of the roche group (six: ro, rog; otcqx: rhhby), announced today two-year follow-up data from the phase iii starglo study. after a median follow-up of 24.7 months, data showed a 40% improvement in overall survival (os) for patients treated with columvi® (glofitamab-gxbm) in combination with gemcitabine and oxaliplatin (gemox) and median os was not reached, compared to 13.5 months for rituxan® (rituximab) plus gemox (r-gemox). the. |
2025-05-22 11:45:00 | Fda Approves Genentech’s Susvimo For Diabetic Retinopathy South san francisco, calif.--(business wire)--genentech, a member of the roche group (six: ro, rog; otcqx: rhhby) announced today that the u.s. food and drug administration (fda) has approved susvimo® (ranibizumab injection) 100 mg/ml for the treatment of diabetic retinopathy (dr), a potentially blinding condition that affects almost 10 million people in the u.s. and more than 100 million people globally. it is the first and only fda-approved continuous delivery treatment shown to maintain visi. |
2025-05-20 14:58:00 |
|
2025-05-20 14:40:00 |
|
2025-05-14 16:00:00 |
|
2025-05-13 01:00:00 |
|
2025-05-12 10:30:00 |
|
2025-05-12 08:30:00 |
|
2025-05-09 00:25:00 |
|
2025-05-06 01:00:00 |
|
2025-04-30 06:54:00 |
|
2025-04-30 01:00:00 |
|

📰 Browse additional press releases for Roche Holding!
Sign up for free or log in✅ Download "The Checklist Value Investor — A Smarter Way to Pick Stocks" — totally free!